Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Combined positron emission tomography and magnetic resonance imaging for breast cancer staging. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2016 Authors' conclusions Description of Technology: Although positron emission tomography (PET) provides information about glucose metabolism, cellular proliferation, and cellular receptor expression, it has limited spatial resolution. Hybrid PET/magnetic resonance imaging (MRI) scanners have recently become available. Compared with PET combined with computed tomography (CT), PET/MRI offers less exposure to ionizing radiation and the ability to study dynamic contrast enhancement. PET and MRI both provide physiological, cellular, and molecular information about the tissues imaged. The anatomical information provided by MRI is superior to that available with CT in soft tissues, and MRI may be superior for detecting metastases in the liver, brain, and bone marrow. Combining PET and MRI technologies using a hybrid technique permits simultaneous acquisition of data and reduced scanning time, and increases patient convenience.
Patient Population: Breast cancer staging with PET/MRI is intended for patients with an initial diagnosis of breast cancer and patients who require restaging after treatment or recurrence of breast cancer. Indexing Status Subject indexing assigned by CRD MeSH Breast Neoplasms; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Neoplasm Staging; Positron-Emission Tomography Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32016000785 Date abstract record published 15/06/2016 |